EVALUATION AND OPTION AGREEMENTEvaluation and Option Agreement • February 26th, 2016 • Vbi Vaccines Inc. • Biological products, (no disgnostic substances) • London
GLAXOSMITHKLINE BIOLOGICALS SA, a company registered in Belgium under number RPM Nivelles – BE – 0440 872 918 and having a place of business at 89, rue de l’Institut, B-1330 Rixensart, Belgium (herein referred to as "GSK") on the other part,
Evaluation and Option Agreement for a Patent LicenseEvaluation and Option Agreement • April 2nd, 2018 • Argos Therapeutics Inc • Pharmaceutical preparations • England and Wales
This Evaluation and Option Agreement for a Patent License ("Agreement"), dated as of February 1, 2018 ("Effective Date"), is by and between Actigen Limited (“Patent Holder”) Pharmstandard International, S.A. ("Prospective Licensor") and Argos Therapeutics, Inc. ("Prospective Sublicensee").
EVALUATION AND OPTION AGREEMENTEvaluation and Option Agreement • November 10th, 2021 • VYNE Therapeutics Inc. • Pharmaceutical preparations • England and Wales
This Evaluation and Option Agreement (“Option Agreement”) is entered into as of April 30, 2021 (the “Effective Date”) by and between, on the one hand, In4Derm Limited, a company incorporated and registered in Scotland with company number SC651132 with a place of business at 15 Luke Place, Broughty Ferry, Dundee, Scotland, DD5 3BN (“In4Derm”), and, on the other hand, VYNE Therapeutics Inc., a Delaware corporation with a principal place of business at 520 U.S. Highway 22, Suite 204, Bridgewater, NJ 08807 (“VYNE”). In4Derm and VYNE may be referred to herein individually as a “Party” and collectively as the “Parties”.
1 EXHIBIT 10.12 EVALUATION AND OPTION AGREEMENT AGREEMENT made as of the 30th day of December, 1996, by and between the Consumer Health Care Division of Pfizer Inc. (hereinafter referred to as "Pfizer"), a corporation organized and existing under the...Evaluation and Option Agreement • January 2nd, 1997 • Nastech Pharmaceutical Co Inc • Pharmaceutical preparations
